Comparative Pharmacology
Head-to-head clinical analysis: GADOBUTROL versus MAGNEVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GADOBUTROL versus MAGNEVIST.
GADOBUTROL vs MAGNEVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gadobutrol is a gadolinium-based contrast agent (GBCA) that shortens T1 relaxation time in magnetic resonance imaging (MRI), enhancing signal intensity in tissues where it distributes. It is a paramagnetic agent that increases the relaxation rate of water protons in the vicinity of the gadolinium ion.
Gadopentetate dimeglumine is a paramagnetic contrast agent that shortens T1 and T2 relaxation times in tissues where it accumulates, enhancing signal intensity on T1-weighted magnetic resonance imaging (MRI). It distributes extracellularly and does not cross the intact blood-brain barrier, but accumulates in areas of disrupted barrier or abnormal vascularity.
0.1 mmol/kg (0.1 mL/kg) intravenous bolus; maximum dose 0.1 mmol/kg per contrast study. Repeat dosing up to 0.2 mmol/kg total during a single session may be considered on clinical judgment.
0.2 mL/kg (0.1 mmol/kg) intravenously, up to 0.6 mL/kg (0.3 mmol/kg) for certain indications, with a maximum of 20 mL per dose.
None Documented
None Documented
Terminal elimination half-life: 1.24-2.23 hours (healthy); may be prolonged in renal impairment (up to 9.6 hours in severe impairment).
Terminal elimination half-life in patients with normal renal function is approximately 1.6 hours. In patients with impaired renal function, half-life is prolonged (up to 30 hours with GFR <30 mL/min).
Primarily renal (90-95% unchanged within 24 hours); less than 0.3% fecal.
Renal excretion of unchanged gadopentetate dimeglumine accounts for approximately 99% of the administered dose within 72 hours. Biliary/fecal excretion is negligible (<0.5%).
Category A/B
Category C
Contrast Agent
Contrast Agent